Back to Guavy Wire

Stocks

Amgen's Q2 Sales Rise 9%, Earnings Beat Expectations Amid Strong Demand for Key Drugs

Guavy AI Editorial Team Published August 6, 2026

Instruments

AMGN

Amgen's second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases.

The California-based biotech company reported quarterly revenue of $10.1 billion, surpassing the average Wall Street estimate of $9.42 billion.

Adjusted earnings per share increased 4% from a year earlier to $6.29 per share, beating analysts' expectations of $5.62.

More on Stocks

Stocks just now

Szeged Prepares for Coca-Cola SZIN Festival with International Headliners

Stocks just now

Coca-Cola Stock Faces Overbought Risk Amid Bullish Long-Term Outlook

Stocks just now

Discontinued Sodas and Drinks That Refuse to Fade Away

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Real-time market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy